Characterizing Burnout in Health Professionals: Insights from the BEATS Study in Portugal

By João L. Carapinha

January 27, 2026

Burnout Health Professionals: Join the BEATS Study Call

Burnout health professionals in Portugal are invited to participate in the BEATS study, an initiative by the Portuguese Laboratory for Healthy Work Environments. Titled “BEATS – Burnout, Expectativas e Ambientes de Aprendizagem e Trabalhos Saudáveis” (Burnout, Expectations, and Healthy Learning and Work Environments), it characterizes burnout health professionals and examines workplace ecosystems as protective or risk factors. Collaboration with the Ordem dos Farmacêuticos urges pharmacists’ involvement for representativeness, using an anonymous 15-minute questionnaire for academic purposes.

Workplace ecosystems profoundly influence burnout health professionals experience, acting as safeguards or amplifiers. The BEATS study explores these dynamics in Portuguese health settings, analyzing environmental factors. It targets active practitioners, spotlighting pharmacists to capture profession-specific trends. This ecosystem lens promotes tailored interventions, blending organizational and worker contexts beyond individual evaluations.

The BEATS study’s questionnaire can be completed in 15 minutes by health professionals in Portugal. It stresses sincere responses with no right or wrong answers, upholding anonymity and confidentiality for research only. Participants can opt in or out freely. Led by Prof.ª Doutora Tânia Gaspar from SPIC/Universidade Lusófona, it meets ethical norms, offers clarification contacts, and falls under National Data Protection Authority oversight—ensuring robust burnout data without privacy risks.

BEATS will likely lead to occupational health costs in Portugal. By pinpointing modifiable ecosystems, it guides retention-boosting interventions, curbing absenteeism and turnover in roles like pharmacy. Results could back modeling of policy interventions towards healthy environments, offsetting healthcare spends and aligning with preventive trends for sustainable healthcare delivery.

Reference url

Recent Posts

PIONEER TEENS Trial Reveals Oral Semaglutide Diabetes Breakthrough for Pediatric Patients

By João L. Carapinha

April 24, 2026

Important results from the PIONEER TEENS phase 3a trial! Oral semaglutide diabetes therapy delivered statistically superior glycemic control compared with placebo in children and adolescents aged 10–17 years with type 2 diabetes. The trial met its primary endpoint with a 0.83% greater reduction i...
Terminal Complement Inhibition: Promising Results in IgAN from the I CAN Trial
Terminal complement inhibition with Ultomiris (ravulizumab) delivered a statistically significant and clinically meaningful reduction in proteinuria at week 34 in adults with immunoglobulin A nephropathy (IgAN) at high risk of progression. According to the prespecified interim analysis of the Pha...
Advancements in Rare Disease Therapies: CHMP’s April 2026 Insights and Economic Implications
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommendations from its 20–23 April 2026 meeting, included a particular focus on rare disease therapies. The CHMP issued positive opinions for five new medicines, three of which carry orphan designation, alo...